Related Experiment Videos
Somatostatin receptors in the orbits
1Department of Ophthalmology, Dokuz Eylül University School of Medicine, Izmir, Turkey.
Clinical Nuclear Medicine
|March 1, 1995
Summary
In-111 pentetreotide imaging shows uptake in Graves' ophthalmopathy (GO) orbits, but its correlation with disease severity is unclear. Limited response to octreotide treatment suggests potential nonspecific binding or limited efficacy in GO.
Area of Science:
- Nuclear Medicine
- Ophthalmology
- Endocrinology
Background:
- In-111 pentetreotide is used for detecting somatostatin receptor (SSR) positive tumors.
- Activated lymphocytes in Graves' ophthalmopathy (GO) may show In-111 pentetreotide uptake.
- Orbital disorders require accurate diagnostic methods.
Purpose of the Study:
- To evaluate the utility of In-111 pentetreotide scintigraphy in Graves' ophthalmopathy (GO).
- To assess uptake patterns and correlation with disease severity.
- To explore the potential of SSR-targeted therapy in GO.
Main Methods:
- SPECT and planar imaging with In-111 pentetreotide in five GO patients, three with necrotizing scleritis, and two with orbital pseudotumor.
- Imaging performed at 4, 24, and 48 hours post-injection.
- Correlation analysis with Werner's classification for GO severity.
Main Results:
- SPECT showed marked, persistent orbital uptake in three of four GO patients.
- No significant correlation between In-111 pentetreotide uptake and GO severity was found.
- Orbital pseudotumors also exhibited positive uptake; necrotizing scleritis showed transient uptake.
Conclusions:
- In-111 pentetreotide uptake in GO orbits may not correlate with disease severity.
- Octreotide treatment showed no clinical improvement in GO patients, questioning SSR-targeted therapy efficacy.
- Nonspecific binding is a potential confounding factor in interpreting In-111 pentetreotide uptake in GO.